Access Program Information
The 10%-15% of breast carcinomas known to be ‘triple negative (TN)’ (not expressing HRs and
not exhibiting overexpression Her2) constitutes 85% of all basal-like tumors, because it is
based on three standard immunohistochemical biomarkers.
In clinical routine, Docetaxel was widely indicated as first-line therapy for breast cancer
patients in adjuvant or neoadjuvant settings. Oxaliplatin,
trans-1-diaminocyclohexane-platinum, may offer advantages over other platinum agents.
Oxaliplatin promotes formation of DNA adducts, preventing DNA replication and transcription
and ultimately causing apoptosis. Oxaliplatin was more potent than cisplatin and the
Oxaliplatin-based regimen was active for the patients of lung cancer, colorectal cancer and
ect. TNBC patients were more sensitive to platinum-based chemotherapy regimens according to
the results of some retrospective studies. There was no report about Oxaliplatin in the
chemotherapy setting for breast cancer patients.
The investigators hypothesized that using Oxaliplatin adding to docetaxel would be feasible
and active in patients with TNLABC because in vitro findings suggest synergism between the
agents. This study was designed to investigate the efficacy and toxicity of
oxaliplatin-based regimen as a neoadjuvant chemotherapy setting in triple negative local
advanced breast cancer patients